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ABSTRACT 
 
Prospective evaluation of musculoskeletal events in patients of Chronic Myeloid 
Leukemia –Chronic Phase treated with Imatinib mesylate AND possible correlation 
with electrolyte imbalances 
Introduction: Tyrosine Kinase inhibitors especially Imatinib have become the 
first choice of therapy in Chronic Myeloid Leukemia (CML).The adherence to therapy is 
an important factor required for achieving Molecular responses.  Myalgia and 
Musculoskeltal pain are one of the common nonhematological toxicities affecting 
adherence.One of the most common hypothesis for this toxicity stated is Phosphate and 
calcium metabolism. We have done a prospective study to look into the incidence of 
Myalgia and Muscoloskeltal pain in our patients and also the abnormalities in serum 
electrolytes and also a possible correlation between the two. 
Patients and Methods : We conducted a prospective observational study         
between January 2011- December 2012 where all new patients of CML without any 
relevant comorbids were included.Samples Of serum electrolytes( serum phosphate, 
sodium ,potassium and Calcium (along with Serum Albumin to check on ionized levels) 
were sent along with a urine spot sample for Creatinine and Phosphate to calculate serum 
phosphate at 0,3 and 6 
th 
month.10 control samples were also sent to check for validation. 
Patients were followed up and hematological responses were recorded at each visit and 
history for any non hematological adverse effect especially myalgia was documented. 
Stastical analysis was done using paired t tests using SPSS software version 13 
Results: 57 patients were included, median age 32y(4-65y),6 pediatric patients 
were included 92% achieved Complete hematological response at the end of first year. 
Myalgia and Musculoskeletal pain were the most common side effects(31%)next was 
hypopigmentation (8%). Grd 1 myalgia (68%) was most common. For serum electrolytes 
a decrease in trend from baseline values for serum Phosphate , Calcium and potassium 
was observed so also there was fractional increase in phosphate in urine. Correlation did 
not show any significant relationship between decrease in calcium and phosphate values 
and myalgia probably because of a small sample size. However decreasing potassium 
values at 3 rd month was having a close correlation (=0.07). Only 1 patient(3%) who had 
Grd 3 myalgia was non compliant. 
Conclusions: Musculoskeletal pain and myalgia are one of the most common 
nonhematological toxicities on Imatinib although they tend to resolve they tend to be 
associated with relative hypokalemia and possibly relative hypophosphatemia and 
hypocalcemia .This probably warrant further study especially in the subset of pediatric 
and elderly patients where bone growth and bone mineral density might be affected 
adversely. 
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INTRODUCTION 
 
 
   
Chronic myeloid leukemia (CML) is a clonal proliferative disorder of 
a pluripotent stem cell involving myeloid, erythroid, megakaryocytic, B, and 
sometimes T, lymphoid cells. CML is classified as a myeloproliferative 
disorder, but is distinguished from these diseases by specific cytogenetic and 
molecular abnormalities. CML is associated with the Philadelphia 
chromosome (Ph) involving a balanced translocation t(9;22) (q34, q11.2), and 
the related break point cluster region-abelson(bcr-abl) chimeric gene.
1 
 
Advances in understanding the disease pathophysiology and molecular 
genetics have yielded a wealth of information regarding CML. The efficacy of 
Imatinib mesylate therapy has radically changed the prognosis of CML. With 
Imatinib, the survival in CML has improved from a median of 3-6 years with 
hydroxyurea and interferon-alpha to an estimated 8-year survival rate of 80-
90%.
 
 
Nearly 30% of patients are nonadherent to Imatinib (i.e. they have 
interruption of the drug because of their own and not because of physicians 
recommendation) this is as per a earlier study done at our centre. 
Nonadherence is because of various reasons and the chances of these patients 
to achieve a complete cytogenetic response(CCyR) becomes remote.
2
  
2 
Patients in nearly all regional cancer centres in India are getting Glivec 
through Glivec International Patient Assistance Program (GIPAP). It is one of 
the most comprehensive and far-reaching cancer access programs ever 
developed on a global scale. 
  
Novartis designed Glivec International Patient Assitance 
Programme(GIPAP) to provide Glivec (Imatinib) free of cost to eligible 
patients in developing countries who meet specific medical and socio-
economic guidelines. Through the Max Foundation, GIPAP also provides 
information and referral assistance to patients, their family members and 
caregivers.  
 
Specifically: GIPAP helps patients who are properly diagnosed with 
Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) 
patients and to patients with c-Kit (CD117) positive unresectable (inoperable) 
and/or metastatic malignant gastrointestinal stromal tumors (GISTs). GIPAP 
helps patients who are not insured, not reimbursed, cannot pay for treatment 
privately, and are in developing countries that have minimal reimbursement 
capabilities. 
 
Considering this and that financial feasibility of second line Tyrosine 
kinase inhibitors is difficult it is important that our patients remain adherent to 
treatment. Some of the nonhematological toxicities of Imatinib cause 
intolerance and thus lead to non adherence too. CML patients who are in 
3 
chronic phase have the most common and worrisome nonhematological 
toxicity as musculskeletal pain and myalgia. 
 
The 5 year follow up data of IRIS (International Randomized Study of 
interferon and STI517 trial ) out of 551 patients on Imatinib who continued 
treatment, muscle cramps and myalgias were present in 38% and 21% of 
patients respectively; grade  3/ 4 cramps were in 1.3 % of patients and grade  
3/ 4 of myalgia was found in 1.5% of patients . The cause of this has been 
unknown and the treatment advised for it is usually calcium supplementation, 
nonsteroidal anti inflammatory drugs (NSAIDs) and tonic water. Many 
hypotheses have been proposed in this regard and one of the closest contender 
is electrolyte imbalances namely of phosphate, calcium and possibly 
potassium. The two main theories behind this are. 
1. Renal loss due to renal tubular dysfunction  
2. Altered bone mineral metabolism 
 
This study will look into the incidence of myalgia and musculoskeletal side 
effects of Imatinib and correlate these events with possible electrolyte 
imbalances in a newly diagnosed patient of CML who will be started on 
Imatinib. 
 The other objectives of this study are to look into non compliance due 
to this particular side effect and effect of NSAIDs and calcium 
supplementation in these patients. 
 
4 
AIM 
Primary outcomes 
 
1. To prospectively evaluate the incidence of musculoskeletal events (i.e. 
myalgia, bony pains & cramps) in CML chronic phase patients started 
on Imatinib. 
2. Correlation of these events with electrolyte changes, namely serum 
calcium, serum phosphate and serum potassium. 
 
Secondary outcomes 
1. To estimate non-compliance because of these events. 
2. Effect of analgesics and calcium supplementation in these patients. 
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REVIEW OF LITERATURE 
 
Introduction 
 Chronic myeloid leukemia (CML) is the most common 
myeloproliferative disorder which has been defined by the presence of 
Philadelphia chromosome (9;22)(q34;q11)  on karyotyping studies or the 
presence of bcr-abl fusion transcript which is in most cases a p210 variant. 
Philadelphia negative CML is a rare entity, the diagnosis of which is not easy 
as cryptic bcr-abl translocation can be present but can get missed during 
cytogenetic analysis. The myeloid cell proliferation involves the blood and 
reticuloendothelial compartments.
3,4
 
 
Historical Perspective 
 It was John Hughes Benett, a pathologist who performed an autopsy of 
a patient who had presented to him with clinical picture of a massive spleen 
which was associated with leucocytosis He published his findings in the 
Edinburgh Medical and Surgical Journal. During the same period Rudolph 
Virchow saw a similar patient and unlike Benett who had concluded that his 
patient had died of the presence of ―purulent matter‖ in the blood, Virchow 
coined the term ―Weisses Blut‖, German for which is ―Leukemie‖. It was in 
1872 that Ernst Neumann described the origin of the disease to be in bone 
6 
marrow. Nearly 100 years later in 1960 the next important step happened 
which was the recognition of chromosome from the cells cultured from the 
blood of chronic granulocytic leukemia. This chromosome resembled a Y 
chromosome but was present in the karyotypes of women with this disease. 
This chromosome came to be known as Philadelphia chromosome, Rowley 
was able to further show in 1973 that it was a truncated version of 
chromosome 22 (termed as 22q-) and was a result of reciprocal translocation 
between chromosome 9 and 22. In 1970 Herbert Abelson had isolated a 
transforming gene from Moloney murine leukemia virus. In the early 1980s it 
was reported that the human counterpart of murine Abelson gene , now known 
as ―abl ― was at human chromosome 9 but was translocated to the Ph 
chromosome in CML. This suggested the possibility that it would be the abl 
gene that would be the cause of CML. Groffen and colleagues reported the 
breakpoint on chromosome 22. This was clustered in 5.8Kilobase region on 
chromosome 22 that they termed as breakpoint cluster region (bcr).
5 
 
 Research in the past two decades has established that it is the activity of 
bcr-abl tyrosine kinase which leads to transformation of hematopoietic cells 
into CML.  
 
 To determine whether P210 bcr/abl can induce chronic myelogenous 
leukemia, Daley et al conducted studies where murine bone marrow was 
7 
infected with a retrovirus encoding P210 bcr/abl and transplanted into 
irradiated syngeneic recipients. Transplant recipients developed a syndrome 
resembling myeloproliferative disorder which closely resembled the chronic 
phase of human chronic myelogenous leukemia.
6
  
 
 The bcr-abl
 
+ leukemias  became the most thoroughly understood of 
human malignancies, in part because of the development of accurate animal 
models for these diseases.
7 
The fact that it proved difficult to identify further 
downstream targets specific to the disease made bcr –abl most attractive 
therapeutic target.
8
 
 
CML in Pre Imatinib Era: 
 In the pre Imatinib era as early as 1860 there were reports of use of 
Fowler’s solution, and prior to radiotherapy, Arsenic was used in the treatment 
of high counts in a patient of CML.
9
  
 
 The first effective palliation was achieved by Radiotherapy which was 
usually directed to spleen; currently the role of radiotherapy is for Total Body 
Irridiation.
10 
 
 Post World War II during the use of alkyaltors, Busulfan was 
introduced in the treatment of CML. It allowed longer periods of 
8 
hematological control but had severe and erratic myelosuppressive side 
effects.
5
 
 Hydroxyurea was introduced in 1972 and had a better toxicity profile 
than Busulfan and in a German /Swiss randomized study it came out as a 
superior alternative when it was compared with buslfan.
11 
 
 It was the use of Interferon-α in CML that led one to ponder on the 
possibility of the idea of cytogenetic remission. Hematologic remissions have 
been noted in the majority of patients using IFNa-2a as a single agent and 
complete cytogenetic remissions (i.e., absence of any Ph+ metaphase by 
conventional cytogenetics) were noted in a minority of patients.
5,12
 
 
 The rate of cytogenetic response was higher in younger patients and in 
those with lower Sokal risk categories and those treated earlier. Although the 
degree of cytogenetic response improved over time, it was uncommon to 
observe cytogenetic responses with further treatment if no reductions in the 
percent of Philadelphia chromosome metaphases were seen during the first 
year of therapy. Because of the considerable side effects from interferon, 
many clinicians chose to stop interferon therapy if cytogenetic improvement 
had not been seen after approximately one year of treatment.
5
 
 
 An Italian trial showed improvement in survival figures when Ara –C 
was added to Interferon-α.13 
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 The only curative option for CML was and remains Allogenic Stem cell 
transplant but in the era of tyrosine kinase inhibitors is usually a third line 
option, unless there happens to be a presence of T315I mutation or progression 
to accelerated and Blast phase.
14
 
 
Development of bcr-abl tyrosine kinase inhibitor:  
 In 1992, Anafi and colleagues reported a tyrphostin, which was related 
to erbstatin, that inhibited the tyrosine kinase activity of bcr-abl and suggested 
that it might be possible to target abl associated leukemias with specific 
compounds. Subsequently, the tyrphostins AG568, AG957, and AG1112 were 
designed as the most specific compounds. Growth inhibition of the CML cell 
line occurred at micro molar concentrations by these compounds and was 
associated with inhibition of BCR-ABL tyrosine kinase activity. Although 
active in vitro, they have not been developed for clinical use.
15
 
 
 In the late 1980s, researchers at Ciba Geigy, started research on the 
identification of compounds with inhibitory activity against protein kinases. In 
one project focusing on protein kinase C (PKC) as a target, a 2-
phenylaminopyrimidine derivative was identified as a parent compound. This 
compound had low potency and poor specificity, inhibiting both 
serine/threonine and tyrosine kinases, but it was the lead molecule and 
10 
following this, with an array of permutations and combinations, several 
molecules came into picture and eventually came STI571, now called Imatinib 
Mesylate, which was highly selective for bcr-abl.
8
 
Mechanism of action of Imatinib 
 Imatinib mesylate (Gleevec, or STI 571) binds to the ATP-binding site 
of the brc-abl oncoprotein and prevents transfer of phosphate from ATP to the 
second messenger. Hence, it prevents further downstream signals which lead 
to cell growth arrest and eventually apoptosis due to lack of growth signals. 
 
 
Figure 1: Mechanism of action of Imatinib
16 
 
11 
 Though designed to target bcr-abl specifically, Imatinib targeted many 
off target kinases; at a Cmax of 4.6µM it inhibits, apart from bcr-abl, the 
following: 
 
 collagen induced discoiddin domain receptor -1, 
 PDGFR-α & β 
 C-kit 
 the macrophage colony stimulating factor(M-CSF) receptor and c-fms. 
 nontyrosine kinase targets include NAD(P)H :quinine oxidoreductase 2 
and some family members of carbonic anhydrase (CA) family of 
metalloproteineases. 
 
 These off target signaling can lead to unwanted side effects and though 
some of these inhibitory mechanisms have come in use in treatment of other 
malignant conditions e.g. GIST, certain side effects are now being explained 
on the basis of these inhibitory actions, such as that of inhibition of bone 
remodeling.
17
 
12 
 
Figure 2 Nonspecificity of Imatinib :inhibitory actions apart  
from bcr-abl
18 
Imatinib era in CML:  Current status of Imatinib as frontline therapy  
 Imatinib has now been the first line therapy in the management of CML 
for nearly a decade. In phase 1 trial by Duker et al, 83 patients who failed 
interferon therapy were given Imatinib in escalating doses ranging from 25 mg 
-1000 mg. Above a dose of 300 mg nearly 31% patients achieved cytogenetic 
response. This lead to important finding of a oral medication which had shown 
remarkable efficacy with lesser toxicity.
19
  
 
 Phase 2 trials began in late 1999 and the drug showed efficacy in all the 
three phases which led to its approval by the Food and Drug administration 
(FDA) in CML resistant to interferon therapy and in the advanced phase of 
disease.
8
  
 
13 
 Phase 3 trial was an open labelled multicentre trial, published in 2003 
in New England journal of medicine, and was a comparison of Imatinib and 
Interferon α with low dose Ara-C. Crossover from one arm to the other was 
allowed. The results published in 2003 were a 19 month follow up which 
revealed a major cytogenetic response (MCyR) in nearly 87% of patients (i.e. 
those who had 0-35% of cells which had metaphase positivity and the rates of 
complete cytogenetic response (CCyR) were 87% in contrast to the other arm 
of Interferon and low dose Ara-C where CCyR was just 14.5%.
20
 
 
 At end of 8 years, 304 (55%) patients were on Imatinib. 45% had 
discontinued treatment due to adverse effects and safety (6%), unsatisfactory 
therapeutic outcome (16%), death (3%), SCT (3%) and other reasons amongst 
which were lack of consent, withdrawal or miscellaneous . No safety issues 
were identified in a long term analysis of serious adverse effects. The results 
were as follows: Estimated EFS at 8 year was 81% and freedom from 
progression to AP/BC was 92%. Estimated OS was 85% at 8 year, and 93% 
when only CML-related deaths and those prior to SCT were considered. Three 
events occurred in year 8: 1 progression to AP/BC and 2 deaths unrelated to 
CML (chronic obstructive pulmonary disease; pneumonia aspiration. The 
annual rates of progression to AP/BC in year 4 to 8 after initiation of therapy 
were 0.9%, 0.5%, 0%, 0%, & 0.4%, respectively. Only 15 (3%) patients who 
14 
achieved complete cytogenetic response (CCyR) progressed to AP/BC, all but 
one within two years of achieving CCyR
21
.
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Monitoring responses on Imatinib therapy
14 
Table 1. Responses on Imatinib: defining complete hematological 
response(CHR), cytogenetic responses and molecular responses 
Definitions of Hematologic, Cytogenetic, and Molecular Response 
RESPONSE BY TYPE DEFINITIONS 
Hematologic Responses 
Complete Hematological Response 
(CHR) 
 
WBC < 10 X 10
9
/L 
Basophils _ 5% 
No myelocytes, promyelocytes, 
myeloblasts 
in the differential 
Platelet count  <450 X 10
9
/L 
Spleen nonpalpable 
Cytogenetic Responses 
Complete (CCgR) 
Partial (PCgR)  
Minor (mCgR)  
Minimal (minCgR)  
None (noCgR)  
 
No Ph + metaphases 
 1% to 35% Ph+ metaphases 
 36% to 65% Ph+ metaphases 
 66% to 95% Ph+ metaphases 
95% Ph+metaphases 
Molecular Responses 
Complete (CMolR) 
by real time quantitative and/or 
nested 
PCR in two consecutive blood 
samples of adequate quality 
(sensitivity > 10
4
) 
Major (MMolR)  
 
 
  
Undetectable BCR-ABL mRNA 
transcripts 
 
 
 
Ratio of BCR-ABL to ABL (or other 
housekeeping genes) <  0.1% on the 
16 
international scale 
Table 2.  Monitoring responses: time frames 
Response  Description of monitoring 
Hematologic At diagnosis, then every 15 days until CHR has 
been achieved and confirmed, then at least every 
3 months or 
as required 
Cytogenetic At diagnosis, at 3 months, and at 6 months; then 
every 6 months until a CCgR has been achieved 
and confirmed, 
then every 12 months if regular molecular 
monitoring cannot be assured; always for 
occurrences of treatment failure (primary or 
secondary resistance), and for occurrences of 
unexplained anemia, leukopenia, 
or thrombocytopenia 
Molecular by RT –PCR Every 3 months until MMolR has been achieved 
and confirmed, then at least every 6 months 
Molecular by Mutational 
analysis 
In occurrences of suboptimal response or failure; 
always required before changing to other TKIs 
or other therapies 
 
17 
 
Duration of treatment with Imatinib
22 
 In a prospective, multicentre, non-randomised Stop Imatinib (STIM) 
study, Imatinib treatment (of >2 years duration) was discontinued in patients 
with CML who were aged 18 years and older and in CMR (>5-log reduction in 
BCR-ABL and ABL levels and undetectable transcripts on quantitative RT-
PCR). 100 patients were enrolled. Median follow-up was 17 months (range 1-
30), and 69 patients had at least 12 months follow-up (median 24 months, 
range 13-30). 42 (61%) of these 69 patients relapsed (40 before 6 months, one 
patient at month 7, and one at month 19). At 12 months, the probability of 
persistent CMR for these 69 patients was 41% (95% CI 29-52). All patients 
who relapsed responded to reintroduction of Imatinib: 16 of the 42 patients 
who relapsed showed decreases in their BCR-ABL levels, and 26 achieved 
CMR that was sustained after Imatinib rechallenge. This reveals that patients 
have to be continued on Imatinib lifelong unless they undergo Allogenic 
transplant and do not have any residual disease detected post same. 
 
 
18 
 
Imatinib use and concerns with Musculoskeletal events-  
 The most common nonhematologic adverse events with a suspected 
relationship to Imatinib were nausea, muscle cramps, fluid retention, diarrhea, 
musculoskeletal pain, fatigue, and skin rashes. 
 
 Only a minority of patients experienced grade 3/4 toxicity. The 
incidence of some specific adverse events was also different according to the 
stage of disease. For example, vomiting and fluid retention were more 
common in patients with advanced-phase disease, whereas musculoskeletal 
symptoms and weight gain were more prevalent in patients in the chronic 
phase.
23
 
 
The importance of Muscloskeletal and joint pains as nonhematological 
toxicity:  
 In a study by David Marin et al, the daily intake of Imatinib is of 
utmost importance in patients who are in cytogenetic remission in order to 
achieve a molecular response. In his study he found the major cause of non- 
adherence in younger patients to be myalgias and musculoskeletal pain. The 
median age for patients with an adherence rate< 90% was 43.8 years 
compared to 53.8 years for patients with a rate greater than 90% (P < .004). 
They found significantly lower adherence rates in patients with muscle 
cramps, and bone or joint pains.
24
 
19 
 Musculoskeletal complaints are a common side effect of Imatinib and 
are manifested as muscle cramps and bone pain. The muscle cramps occur 
mainly in the hands, feet, calves, and thighs. The pattern, frequency, and 
severity of cramps are usually constant over time, and they may resemble 
titanic contractions. Some patients relate cramps to exertion or describe night 
time occurrence. Bone pain and arthralgias have been reported by 20% to 40% 
of patients. Their onset tends to be in the first month of therapy, and they 
frequently abate after a few months. The symptoms most frequently affect the 
femurs, tibias, hips, and knees. Bone or joint pain can be severe and disabling 
and may be strikingly asymmetric. In some cases, imaging studies were done 
but failed to detect abnormalities.
23
 
 
Electrolyte imbalances associated with Imatinib and their association with 
myalgia 
25
 
 
HYPOPHOSPHATEMIA i.e serum Phosphate level< 2.7mg/dl (2.7mg/dl- 
4.5 mg/dl) :  
 This is the most common electrolyte imbalance associated with 
Imatinib. The most common medical causes of hypophosphatemia described 
in literature are - 
 Increased renal loss due to tubular defects 
 Drugs which cause phosphaturia, 
 Hyperparathyroidism, 
 Vitamin D deficiency 
20 
 The clinical manifestations of mild hypophosphatemia include 
myalgias, weakness, anorexia.  Chronic severe depletion may be manifested 
by pain in muscles and bones.  
 
 The phosphate levels should be monitored in a fasting state as there is 
an impact on serum levels of phosphate done on a post prandial sample. Spot 
urine value of phosphate > 20mg/dl suggests phosphate loss in urine. 
Phosphate excretion can be measured either from a 24-hour urine collection or 
by calculation of the fractional excretion of filtered phosphate (FEPO4) from a 
random urine specimen. The formula used to make the latter calculation is the 
same as that for the fractional excretion of sodium: FEPO4 = [URINE PO4 x 
PLASMA Cr x 100] ÷ [PLASMA PO4 x URINE Cr] where U and P refer to 
the urine and plasma concentrations of phosphate (PO4) and creatinine(Cr). 
 
 Low phosphate excretion — Daily phosphate excretion should be less 
than 100 mg and the fractional excretion of phosphate should be well below 
five percent (normal value is five to 20 percent) if the kidney is responding 
normally and renal phosphate wasting is not the cause of the 
hypophosphatemia. 
HYPOCALCEMIA i.e serum calcium levels < 8.4mg/dl (normal levels -
8.4-10.2mg/dl) 
 This is the second most common abnormality which was detected in 
patients on Imatinib, Hypocalcemia increases excitation of nerve and muscle 
cells, primarily affecting the neuromuscular and cardiovascular systems. 
21 
Extensive spasm of skeletal muscle causes cramps and tetany. In true 
hypocalcemia serum ionized calcium is taken into account. Some common 
medical causes stated are 
 Decrease intake or absorption- Malabsorption, small bowel 
bypass  
 Increased loss- Diuretic, alcohol abuse 
 Decreased resorption from bone- use of zolendronic acid 
 Endocrine disorders-Hyoparathyroidism 
 
HYPOKALEMIA i.e serum levels<3.5mg/dl (normal levels 3.5-5.2mg/dl)–  
 Described only in case reports in patients who are on Imatinib, this is 
also a possible cause of myalgia and muscle spasms but does not cause 
arthralgia /bony pains 
 Decreased intake 
 Renal Potassium loss- due to increase aldosterone levels, 
Fanconi syndrome, diuretics 
 Loss through extrarenal routes- villous adenomas, Zollinger 
Ellison syndrome (ZES), laxative abuse 
Musculoskeletal pain/ myalgia inpatients on Imatinib and possible 
association with electrolyte imbalances- existing literature 
 The treatment which has been advised by NCCN and other literature 
evidence states that calcium supplementation is an important treatment aspect 
in the management of musculoskeletal pain along with fluids supplementation. 
22 
The cause of this pain has not been quite clear, however there have been 
reports that hypocalcemia and hypophosphatemia might be associated with 
these symptoms.  
 
 In a case series reported by Zekri et al, they found a sustained fall of 
calcium levels in their patients.
26
 Prior to this study they had studied an index 
case where they had found a similar trend of fall and there was associated 
myalgia and musculoskeletal symptoms in that patient. The probable 
hypothesis given for hypocalcemia by them was that  
1. Imatinib was acting on the c-kit receptor of the renal tubule and causing 
hypocalcemia 
2. Or Imatinib might be causing nonspecific inhibition of calcium 
channels in tubule which might be leading to same 
 
Figure 3 Changes in adjusted serum calcium levels in the index case : 
courtsey Zekri et al
26 
23 
 The renal tubule affection also has been described by Rodrigo Azevedo 
de Oliveira
27
 et al where they described a patient who had acute tubular 
necrosis which was related to Imatinib and this eventually led to electrolyte 
imbalances. The hypothesis given by them was that Imatinib inhibited  
PDGFR –α in proximal tubules and c-kit receptor in distal tubules which led to 
hypophospahatemia and hypocalcemia respectively, but the case reported by 
them did not have any musculoskeletal symptoms and was on Imatinib for past 
4 years. 
 
 Likewise another case report by Helene Francois et al28 showed 
development of partial Fanconi syndrome with patient having 
hypophosphatemia, hypouricemia and glycosuria. The renal biopsy done 
showed vacuolations in the proximal renal tubule. This patient also developed 
myalgia when the treatment was started. They hypothesized that PDGF 
pathway inhibition which is responsible for regeneration of proximal renal 
tubule is inhibited by Imatinib hence it could cause Fanconi syndrome. 
24 
 
Figure 4: Electronmicrograph showing vacuolation in proximal renal 
tubule
28 
 
 
 
 The recent research by Berman29 et al highlighted the possibility of 
effect of Imatinib causing hypophosphatemia as a part of effect of Imatinib on 
bone metabolism. They have hypothesized that the drug acts on bone by 
inhibition of osteoclast function directly by inhibiting PDGFβ and indirectly 
by inhibiting PDGFα receptor present on osteoblasts. This eventually leads to 
decreased bone remodeling and thus decreased calcium and phosphate in the 
25 
serum and since deceased ionized calcium can induce hyperparathyroidism, 
this eventually leads to increased phosphate excretion and decreased calcium 
excretion. 
 
 Their study was based on a set of 16 patients who they found on 
retrospective analysis to be having low serum phosphate and these patients 
were on Imatinib either for CML chronic phase or for Gastrointestinal stromal 
tumor (GIST). They found that those with low phosphate levels had increased 
levels of PTH (parathyroid hormone), low to normal levels of calcium and 
high levels of phosphate being excreted in urine (spot test). The article 
published by them in NEJM in 2006 May was followed by a Letter to Editor 
which was written by Dr Samantha Owen from Novartis, which stated that 
although hypophosphatemia of Grade 2 or above was mentioned in nearly 
50% of the patients  (Common Toxicity Criterion), it was reported only in 3% 
of patients eventually as an adverse event. So, probably, low Grade of 
hypophosphatemia went under reported for which Novartis advised the need to 
continue monitoring phosphate levels in patients who are on Imatinib, as a 
possible effect on bone mineral metabolism is possible.
30
 
 
 The flaws in the study accepted by the author were also stated in 
another letter to the editor which mentioned them as follows: 
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1. No measurement of baseline phosphate levels uniformly in all the 
patients studied. 
2. Calcium levels were not corrected for albumin levels in the study  
3. Blood sampling done was not standardized with respect to time and 
fasting status. 
4. Small number of patients. 
 
 The authors had earlier in the original article mentioned their reasons 
for the delayed sampling of phosphate and also explained that despite the 
expectation that postprandial phosphate levels will be high they still got a low 
levels of serum phosphate levels and also the PTH levels were high which 
confirmed their hypothesis. 
 
 In the same edition of the journal Joensuu and Reichardt31 present data 
on 11 patients in which they did a longitudinal follow up of 11 patients, of 
which, 9 patients (82%) had a lower mean levels of plasma phosphate levels 
and these patients were on Imatinib 400mg which was being given as adjuvant 
treatment for GIST. They found that the plasma phosphate levels returned to 
normal after the discontinuation of the drug and that none of the patient had 
any skeletal event documented. 
 
 Another similar study by Susannah O’Sullivan et al planned a longer 
follow up with similar parameters as studied by Berman et al based on a 
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similar hypothesis, with the objective of studying the biochemical and skeletal 
effects of Imatinib with long term treatment.
32
 Their follow up period was 2 
years, the study design was prospective and all patients were of CML on 400 
mg of Imatinib. They had 9 patients in their study and they concluded 
similarly that there was decrease in calcium and phosphate levels starting at 
their first follow up period of 3 months. It was also documented that at a 
period of 18 months, these levels, although lower than baseline at 18 months, 
were not quite different when compared at 6 monthly follow up.  They also 
demonstrated, like Berman et al, mild increase in PTH levels compared with 
baseline but this again plateaued at three months. Also studied were the 
markers of bone resorption which showed an initial increase followed by a 
decrease in levels, i.e., there was a biphasic effect. They also found an increase 
in bone mineral density at the end of two years. They also concluded that there 
was no evidence for phosphaturia due to Fanconi syndrome causing depletion 
of phosphate levels as they had monitored glucose and amino acids in the 
urine at 0 and 3 months respectively.  
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Figure 5: Hypothesis of how the sequence of events lead to 
hypophosphatemia in patients who are on Imatinib by Berman et al
29 
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 Kate Vandyke et al17 in a review article supported the theory of Berman 
et al and explained that the receptor required for differentiation of osteoblast 
was PDGFR which was inhibited by Imatinib and thus Imatinib decreases 
their proliferation but increases their activity. For osteoclasts, which are 
actually derived from monocyte/macrophage lineage, the effect of Imatinib 
was on c-fms receptor, c-kit receptor and a non specific action was on 
carbonic anhydrase II enzyme which is actually responsible for resorption of 
bone and is secreted by the resoptive surface of osteoclasts. They concluded 
that although the long term effect of Imatinib was not known, it could cause 
decreased bone turnover as caused by microfractures by prolonged use of 
bisphosphonates. 
 
Figure 6 Inhibition of PDGFR in osteoblast precursor and c-fms and c-kit 
in osteoclast precursors by Imatinib
17 
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 The largest series available till date, by S.Osorio et al, is a retrospective 
analysis of 36 patients.
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 The aim of the study was to find the metabolic cause 
of cramps and musculoskeletal symptoms. They studied several parameters of 
phosphate and calcium imbalances along with renal functions in 36 patients 
who have been on Imatinib. Most of these patients had been on Imatinib for a 
median period of nearly four years. These patients were being followed up 3 
monthly and the investigations done revealed hypophosphatemia over time, 
and a decrease in trend of calcium levels but no definite hypocalcemia. They 
did not find any correlation that would suggest secondary hyperparathyroidism 
as the cause of hyperphosphatemia, and since they found that there was lesser 
tubular reabsorption rates, they hypothesized renal tubule c-kit receptor being 
inhibited by Imatinib which causes decreased phosphate reabsorption. They 
also found in their study a correlation between hypophosphatemia and better 
cytogenetic responses in their patients. 
 
Impact of hypophosphatemia in pediatric patients on Imatinib
33 
 Imatinib was licensed for the use in children by the FDA in 2003 for 
CML. Doses for children are different form adults. Doses of 260 to 340 mg/m
2
 
give drug exposures similar to the 400 to 600 mg adult dosage levels; 
therefore, the starting dose in children should be 300 mg/m
2
 orally once daily 
(maximum absolute dose, 400 mg). The recommended pediatric doses for 
CML-AP are 400 mg/m
2
 daily (maximum absolute dose, 600 mg) and for 
CML-BP 500 mg/m
2
 daily (maximum absolute dose, 800 mg). 
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 There is increasing evidence now that hypophosphatemia in patients on 
Imatinib is involved in dysregulated bone metabolism. There have been 
studies which have shown that when given in prepubertal age group it can 
cause decrease in longitudinal growth of the child because of possibly 
premature closure of growth plate. Hence it becomes important to regularly 
monitor growth of the child along with the desired cytogenetic responses at 
appropriate time frames so that an alternative treatment strategy can be 
worked out when needed for these patients, which is usually allogenic 
transplant. 
 
Options for patients who develop musculoskeletal pain /myalgia on 
Imatinib-“INTOLERANCE”14,34 
 There is enough data now that there is minimal cross intolerance of 
second line Tyrosine kinase inhibitors when given in case of intolerance to 
Imatinib. With reference to myalgia there is less of it associated with second 
generation agents as these are more specific and have more affinity towards 
bcr-abl as compared to Imatinib. Any grade myalgia reported with nilotinib at 
a dose of 300mg BD was 7% and 6% in those who received 400 mg BD. 
Similarly, for Dasatinib, myalgia of any grade was present in 6% of patients. It 
is also stated that the hypophosphatemia caused by both these drugs is 
significant. 
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Below is a table with comparative results from three drugs 
Table 3 
AE Imatinib Nilotinib Dasatinib 
Fluid retention +++ mainly low 
grade 
(+) (+) 
Nausea, diarrhea, 
vomiting 
++ (+) (+) 
Pleural effusion - - ++ 
Myalgia +++ (+) (+) 
QTc prolongation + + + 
ALAT/ASAT/biliru
bin increase 
+ ++ + 
Lipase/ amylase 
increase + 
++ (should not be given 
in case of preexisting 
pancreatitis) 
+ 
Glucose levels Hypoglycemia Hyperglycemia Constant 
Hypophosphatemia ++ + + 
Rash, pruritis + ++ (+) 
Anemia + + + 
Neutropenia ++ + + 
Thrombocytopenia + + ++ 
33 
 With the definition of Imatinib intolerance getting more precise it is 
important to switch over to second generation drug so that adherence to the 
drug can be maintained. 
 
The intolerance to Imatinib is defined as following 
(1) any life-threatening grade 4 nonhematological toxicity 
(2) any grade 3/4 nonhematological toxicity that has recurred despite dose 
 reduction 
(3) any grade 2 nonhematological toxicity that persists for more than a 
 month despite optimal supportive measures 
(4) grade 3-4 hematological toxicity that is unresponsive to supportive 
 measures and would require dose reductions below the accepted 
 minimal effective dose. 
 
 This study is relevant because there is limited information on this 
particular and important side effect of Imatinib. The available prospective 
studies are very few, with only small number of patients, and there is no 
published literature from the Indian subcontinent on the subject.  
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PATIENTS AND METHODS 
 
 
 
Study design This is a Prospective Observational study 
 
Inclusion criterion 
 
 Between the period of January 2011-December 2012 all new cases of 
chronic myeloid leukemia who were to be started on Imatinib in our hospital 
and did not have previous exposure to the drug prior were included. 
 
Exclusion criterion:  
– Patients presenting with baseline musculoskeletal disease as 
 Rheumatoid Arthritis,SLE. 
– Patients with deranged renal function: Cr>1.5mg/dl. 
– Patients on drugs other than Imatinib which are known to produce 
 myalgia eg. Statins , HAART therapy.  
– Prior to sampling for electrolytes, acute causes known to cause 
 electrolyte imbalances eg. diarrhea, emesis, poorly controlled diabetes, 
 tumor lysis  were to be excluded. 
 
Methods 
 We at Cancer Institute (WIA) have a CML outpatient clinic on 
 Thursday where Chronic Myeloid Leukemia patients are followed up. 
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 History of the patient was recorded especially with respect to any 
 baseline history of myalgia and musculoskeletal event. After checking 
 that patient is not in tumor lysis and also not any other medication 
 known to cause myalgias, patient’s baseline (prior to starting Imatinib) 
 blood sample was collected preferably during fasting period or 
 otherwise prior to 11 AM for analysis of serum electrolyte panel which 
 includes Serum Phosphorous, Serum Calcium, Serum Potassium and  
 Serum Sodium also Serum Creatinine along with Serum Albumin (for 
 calculation of ionized serum calcium levels). This was collected along 
 with a spot urine sample for analyzing spot urine creatinine and spot 
 urine Phosphorus. Likewise, after starting Imatinib the date of starting 
 the drug was noted and these patients were followed up with similar 
 sampling done at 3 months and 6 months. 
 Nonhematological toxicity was recorded, and if myalgia 
 /musculoskeletal pain was present, detailed history was noted. Grading 
 for myalgia/musculoskeletal event was done as per Common Toxicity 
 Criterion version 2.0. 
 
 Compliance issues related to any cause were noted and also if it was 
 related to musculoskeletal event was recorded. This was highly 
 dependent on patient’s history and any nonadherence to the drug which 
 exceeded more than 1 week was considered significant and recorded.
2
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 At follow up of 3 months the patients were evaluated whether they 
 achieved Complete hematological response or not. Due to logistical 
 aspects monitoring by FISH (Fluoroscent in situ Hybridization) was 
 done usually at end of 1 year. 
 
 In case of patient developing myalgia and Musculoskeletal pain, patient 
 was started on NSAID’s for a period of 5 days and Calcium tablets 
 were also prescribed 500mg daily once. 
 
 Response of myalgia and musculoskeletal event was recorded on next 
 visit. 
 Samples of 10 controls Were also sent for comparision and validation. 
 
Grade  
Table 4 : CTC response criterion used for grading 
Adverse event 0 1 2 3 4 
Myalgia 
(muscle pain) 
None Mild pain 
not 
interfering 
with 
function 
Moderate 
pain or 
analgesics 
interfering 
with 
function, but 
not 
interfering 
with 
activities of 
daily living 
Severe 
pain or 
analgesics 
severly 
interfering 
with 
activites 
of daily 
living 
Disabling  
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 Measurement of the following and serum creatinine  and spot urine 
tests were done at biochemistry lab at our institute. The following blood and 
spot urine tests were done 
1. Serum Sodium (Na+) 
2. Serum Potassium (K+) 
3. Serum Phosphate (PO4) 
4. Serum Calcium along with Serum albumin 
5. Serum creatinine 
6. Spot urine Phosphate 
7. Spot urine Creatinine 
 Serum and urine electrolyte measurements were done with automated 
analyzer A-25(BIOSYSTEMS©) 
 
Figure 5: Automated Analyzer A-25(BIOSYSTEMS©) 
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 Formulas used 
1. Fractional excretion of phosphate in urine 
 FEPO4 = [URINE PO4 x PLASMA Cr x 100] ÷ [PLASMA PO4 x 
URINE Cr]. 
 NORMAL VALUES: between 5-20% 
2. Corrected Calcium = [0.8 * (Normal Albumin - Pt's Albumin)] +Serum 
Calcium. 
 
 Statistical methods used for analysis :  
 The descriptive statistics of the variables studies were represented as 
two way tables. The categorical factors were represented by the number and 
frequency (%) of cases. The continuous variables were represented by 
measures of central frequency (like mean, median) and deviation (standard 
deviation and range). For variables measured on a continuous scale, when 
testing for two groups, Student ―t‖ test  was used to test for statistical 
significance in the differences of the two means. Analysis was carried out 
using SPSS version 13 software. 
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Flowchart of Patient Follow Up: 
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RESULTS 
 
 
 Fifty seven patients were included in the study over the year 2011. 
Median age was 32  years  (4-65years) of which there were 44 males and 15 
females with a male : female ratio of 1.94:1. Of  these, 2 patients were not 
taken for the study as 1 patient after baseline investigations was revealed to be 
on antipsychotic medications and diuretics and another patient progressed 
within 3 months of starting Imatinib into blast crisis. The age distribution is 
shown in the pie chart below.  
 
 
Graph : 1 
 
 
 Dose of Imatinib(mg): 6 patients in pediatric age group were started 
on Imatinib at a dose of 300 mg/m
2 
 and rest 51 adult patients were on 400mg. 
 
41 
 
 
 
Graph 2 
 
 Hematological Response was monitored in patients at initial visits 
which included  the documentation of presence of complete hematological 
response. 53 (92%) patients achieved Complete hematological response at the 
end of 3 months and 2 patients with ongoing hematological response attained 
CHR just after the 3rd month. However, they were continued on same dose of 
Imatinib. 
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Graph 3 
 
NON HEMATOLOGICAL SIDE EFFECTS 
 The side effects noted are as stated above. Myalgia and musculoskeletal 
pain were the  most common side effects noted (54%). The next common were 
hypopigmentation  (14%), nausea (7%) and pedal and facial edema which 
were noted by the patients but  resolved over a month without any medication. 
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Graph 4 
 
 
Musculoskeletal events and myalgia  
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Graph 5 
 
 Musculoskeletal pain /myalgia was present in 31 patients (56%), of 
which 21 (68%) had Grd 1 myalgia and 7 had Grd 2 (22 %) and 3 patients 
(10%) had grade 3 myalgia. 
 
 Time of onset of myalgia /musculoskeletal pain: this event was 
documented within 1 month in 25 patients (80%), 3 patients had it in 2
nd
 
month of starting Imatinib. 1 patient had myalgia in the 5
th 
month. 
 
 
Graph 6 
 
 Site of Myalgia- Myalgia was generalized in 30 patients, i.e. they 
complained of pain in extremities and back pain, there was no diurnal 
variation observed, 1patient presented with lower back pain.  
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 MYALGIA/MUSCULOSKELETAL PAIN ON 3
rd 
MONTH 
FOLLOW UP, 52 patients (91%) did not have any myalgia or 
musculoskeletal pain. 
 
Effect of adding analgesics and calcium supplementation: 
 
 Response was present in 29 patients when they were followed on next 
visit but myalgia persisted in 5 patients although it was grade 1 without any 
interference in activity of daily living. 
 
 
Graph 7 
 
 Myalgia/musculoskeletal pain on 6
th 
month follow up: Only 1 patient 
had grade 1 myalgia persisting at 6 monthly follow up (1.7%). 
 COMPLIANCE ISSUES: 1 patient was non compliant due to 
myalgia, he had grd 3 myalgia which was present within 1month but resolved 
with analgesic use. 
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TREND OF SERUM ELECTROLYTES IN PATIENTS OF CML ON IMATINIB 
Table 5 
 
 
Mean Serum 
creatinine 
mg/dl (+/-SD) 
Mean 
Serum sodium 
mg/dl (+/-SD) 
Mean 
serum 
calcium 
mg/dl(+/-
SD) 
Mean 
serum 
potassium 
mg/dl (+/-
SD) 
Mean serum 
(+/-
SD)phosph 
mg/dl 
Mean urine 
cr (+/-SD) 
Mean urine 
phosphate 
value (+/-
SD) 
Mean urine 
fractional 
phosphate 
excretion% 
(+/-SD) 
Baseline 
(n=57) 
0.74(+/-.18) 133.32(+/-3.73) 8.93(+/1.34) 4.17 (+/-.60) 4.32(+/-1.170 53.66(+/36.20) 34.64(+/26.62) 20.82(+/-30.93) 
    3m 
value 
(n=47) 
0.80(+/.14) 133.40(+/-2.38) 8.66(+/1.19) 3.85(+/-.47) 3.69(+/-1.04) 50.33(+/43.13) 29.71(+/28.19) 22.61+/-30.14 
   6m 
value 
0.75 132.62 8.70 3.876 3.557 54.76 49.32 34.89 
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There is a trend of values being noticed in the following electrolytes 
 Mean serum phosphate levels decreased over a period of time. The 
trend over period of time was not statistically significant when baseline levels 
were compared with 3
rd
 month level by performing a 2 tailed t test (p value = 
0.012). Hypophosphatemia (serum phosphate levels < 2.7 mg/dl) was present 
in 7 patients at 3
rd
monthly evaluation. The phosphate levels at 3 
rd 
and 6 
th
 
month was present in 47 and 21 patients respectively. 
 
 Likewise increase in urine fractional phosphate excretion was noted but 
was not statistically significant (p=0.573). This value at baseline could be 
obtained in 37 patients, in 41 patients at 3 month of follow up and in 21 
patients at 6 monthly follow up. 
 
 There was also a trend noted for decrease in mean serum calcium levels 
although again not statistically significant (p=0.3). There were 28 patients who 
had levels lower than 8.7 mg/dl at 3 
rd
month, although the serum albumin 
levels were normal (data for 47 patients present). 
 
 There was no significant trend noted in mean serum sodium level over 
a time period neither was any statistical significance noted when baseline 
levels were compared with 3
rd
monthly levels. 
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 There was a decrease in mean serum potassium levels noted at 3rd 
month with respect to values but again there was no statistical significance 
noted. 
 
 To check the validity of the electrolyte tests there was a panel of serum 
electrolyte and urine tests( for spot phosphate and spot creatinine) was 
performed taking 10 normal controls. T test was used to check for statistical 
differencesThere was a statistically significant higher  values of serum calcium 
levels of controls with respect to that of patients on Imatinib(,p value at 3 
months 0.005 and at 6 month 0.001). 
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Graph 8 (above),9 (below) 
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Myalgia and Musculoskeletal pain and correlation with Electrolyte 
imbalances when compared at 3
rd
 month. 
Table 6 
Parameter at 3 m 
(mg/dl) 
Myalgia present 
N=25 
Myalgia absent 
N=22 
P value 
Serum phosphate 3.60 3.79 0.56 
Serum calcium 8.6 8.7 0.71 
Serum potassium 3.79 3.84 0.073 
 
 Serum phosphate levels were compared in patients who had a 
musculoskeletal event versus those who did not have a musculoskeletal event 
by paired t test .The serum phosphate levels were done in 47 patients at the 
end of 3
rd
month and these patients were taken into analysis  The following 
was the distribution amongst these 47 patients.  
 
 There was no significant differences in the mean values of calcium in 
patients with and without myalgia at 3
rd
 month. 
 
 Serum potassium levels were also compared within  the cohort of 47 
patients at 3 
rd 
month who had myalgia and amongst these patients there was a 
near significant correlation(p=0.07) between patients who had myalgia and 
51 
those with no event i.e. the mean potassium values were lower in patients who 
had myalgia  than in those who did not have it. 
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Graph 10 patients with relative hypokalemia at 3rd month had more 
myalgia/musculoskeletal pain when compared to those with higher values 
 
 However in 1 patient who had myalgia persisting at the end of 6 
months we found the following trend of electrolyte disturbances as previously 
described a similar trend as seen in the cohort was observed. 
 
 
 
 
 
 
 
 
myalgia 
serum potassium 
(3m) 
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Graph 11 
 Amongst pediatric  age group, 1 patient age of 5 years had diminished 
or no gain in height as a main symptom . After 1 year on Imatinib although he 
attained CHR within 3 months. He also had low phosphate levels and increase 
in fractional excretion of phosphate levels.  
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DISCUSSION 
 
 
 
Musculoskeletal pain and myalgia are accounting for significant 
nonhematological toxicity in patients who are started on Imatinib as shown in 
our study as well as in previous clinical trials on Imatinib, including IRIS 
study.  
 Myalgia/Musculoskelatal toxicity incidence reported 
 
Table 7 
Studies 
looking at 
incidence of 
myalgia 
Patients on 
Imatinib 
Musculoskeletal Pain& 
myalgia (all grades) 
Median dose of 
Imatinib 
IRIS 
trial
20
(newly 
diagnosed 
CML patients 
included) 
551 38.3% & 21% 
(Grd 3/ 4 =2.7, 1.5%) 
400 mg 
 
Phase 1 trial 
for Imatinib
19 
83 43% Dose range from 
25 mg -
1000mg(median 
not specified) 
54 
Our study 57 54% (Grd 3 toxicity 1% , 
Grd 4 not present) 
400 mg 
 In IRIS study they have reported myalgia and musculoskeletal pain 
separately, but it was not so reported in the phase 1 trial of Imatinib, we have 
not analyzed this separately. As the hypothesis given by Berman et al 
29
is 
same for both these side effects and the phase 1 trial for Imatinib too did not 
report it separately; we considered it as one side effect. The incidence of our 
grade 3 toxicities are same as that found in IRIS trial although we did not 
observe any Grade 4 toxicity in our patients. As reported in literature
23
 most of 
the patients report this side effect within 1 month of starting Imainib, we also 
found that nearly 80% of our patients had this as a side effect in first month of 
therapy. 
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Trend of Serum Electrolytes in patients who are on Imatinib and correlation with Myalgia/ Musculoskeletal pain. 
 
Serum and urinary phosphate levels in patients in Imatinib 
 The most common electrolyte imbalance reported in literature is decrease in phosphate levels
30,34
 and this is associated 
with altered bone mineral metabolism.
29
 
 
Table 8:  
 
Studies as in 
literature 
Serum Phosphate (mean value+/- SD) at 
following months 
FRACTIONAL EXCRETION OF 
PHOSPHATE% 
Correlation between 
phosphate imbalance 
and myalgia/ 
musculoskeletal pain 
0m 3m 6m 
12m 
 
0 3m 6m 
Susannah O’Sullivan 
et al
31
(CML patients: 
prospective study )
 
Observed a fall in serum Phosphate levels between 
0-3months but stabilized after that (n=9) 
Phosphaturia increased between baseline 
and 18months 
Not studied 
Osorio et al
32 
 (CML patients 
:prospective study)
 
3.7 (+/-
0.6) 
 n=36) 
2.98 (+/-
0.66) 
(n=36) 
3.02 (+/-
0.48) 
(n=34) 
2.84 (+/-
0.5) 
(n=27) 
The median 
value at 12 months was 77.5% (range, 49–
83) (normal value > 79%). 
No correlation found 
Our study (N=57) 
(CML patients: 
prospective study) 
4.3 +/-
1.17 
(n= 56) 
3.69+/-
1.0 
(n=46) 
3.5 +/-0.6 
(n= 21) 
X NA 20 (+/-
5.5) 
(n=37) 
22.6(+/-
30.14) 
(n=41) 
34.89 (+/-51) 
(n=21) 
No correlation found 
p=0.56 
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 Osorio et al tried to correlate the musculoskeletal events with serum 
phosphate. They found that decrease in phosphate levels occur and found a 
level below 2.5 mg/dl in 14 patients over follow up. Their follow up period 
was 12 months and they found persistent decrease in phosphate levels unlike 
the study by Sussanah O’Sullivan who observed a fall in serum phosphate 
levels over the first 3 months but thereafter no fall in serum phosphate was 
noticed. Both the authors confirmed the hypothesis that there is secondary 
hyperparathyroidism as PTH levels were increased on follow up studies. We 
also found an increase in phosphaturia over a period of time and this coupled 
with our finding of hypocalcemia supports the hypothesis by Berman et al that 
there could be a possibility of secondary hyperparathyroidism present during 
intake of Imatinib, though we could not carry out serum PTH studies because 
of financial constraints. 
 
 Another possibility of hypophosphatemia caused by Imatinib given by 
Osorio et al was that it is acting on the c-kit cells of renal tubules; however 
they did not measure other parameters of renal glycosuria which could be 
caused by Fanconi syndrome as proposed by Helene Francois et al. However, 
this hypothesis has been rejected by Kate Vandyke et al in his review article 
stating that this mechanism is only stated in case reports and is not a consistent 
observation. 
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 Serum calcium levels in patients on Imatinib: Decreased levels of 
serum calcium have been described by Berman et al
29
 and by Kate Vandyke et 
al
17
 as a primary event which triggers PTH levels which in turn cause 
hypophosphatemia. This hypocalcemia is caused by decreased bone turnover 
due to inhibition of resorption activity of osteoclasts by Imatinib. The serum 
calcium levels observed and their correlation with myalgia in various studies 
were as follows:Table 9 
 Serum Calcium levels over a 
time period of 0, 3, 
6months(mg/dl) 
Correlation with 
myalgia 
Osorio et al
32 
36 patients studied 
prospectively 
Reported diminished levels over 
time:  0.38+/- 0.08(3m), 0.45 +/- 
0.09 (6m) and 0.37+/- 0.08 
mg/dl(12m) 
No correlation observed 
Zekri at al
32 
16 patients on adjuvant 
Imatinib for GIST 
At the start of Imatinib 
treatment, all patients had 
normal serum calcium levels 
(mean 9.8 ± SD 0.44 mg/dl). 
All patients exhibited a rapid 
and sustained fall in adjusted 
serum calcium during treatment 
with Imatinib to 9.2 ±0.30 mg/dl 
at 6 months 
Proposed a correlation 
that relative 
hypocalcemia may cause 
hypexcitability at 
neuromuscular junction 
and can cause myalgia 
and cramps based on a 
index case, however 
failed to establish any 
significant correlation 
Susannah O’Sullivan et al 
 
change from baseline -0.3 (-0.5, 
-0.1) mg/dl   p <0.05 
Not studied 
Our study  
 
0 month 3month 6month No correlation observed  
p value= 0.71 
8.9+/-
1.3 
(n=57) 
8.6+/-4.0 
(n=46) 
8.7+/- 
3.8(n=21) 
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 Although the studies looking at calcium metabolism were showing a 
decreased trend of calcium, there was no frank hypocalcemia. Likewise, we 
also never got any patient with calcium levels less than 7.0 mg /dl. We have at 
least one value for serum albumin for most of the patients unlike the above 
studies which have looked stringently into the ionized calcium levels for 
patients at every visit. The observations of Zekri et al that relative 
hypocalcemia may be the cause of myalgia/ musculoskeletal pain were 
initially based on an index case of GIST on adjuvant Imatinib who had 
hypocalcemia and severe myalgia and on stopping Imatinib both resolved. 
They further studied this prospectively in 16 patients and found that there was 
significant reduction in calcium values at 6 months when compared with 
baseline. This study highlights the important aspect that the electrolyte 
imbalance and probably myalgia is not dependent on the underlying disease 
but is being caused by the drug and that it can be reversed once the drug is 
stopped.  
 
Imbalances of Potassium and association with musculoskeletal pain and 
myalgia: 
 Imbalances of serum potassium have not been explained in literature in 
patients who are on Imatinib. In our patients, the mean potassium levels at 3 
months were lesser than compared with baseline values (baseline value of 4.20 
and 3 
rd 
month potassium value of 3.85, p value =0.57). However the there was 
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a trend towards association of myalgia in patients who had low potassium 
levels (p=0.07). This finding may have been probably more significant with 
more patients in the study and further follow up and this finding could support 
renal tubular dysfunction effect of Imatinib. 
 
Compliance issues and Myalgia and Musculoskeletal pain: 
 In our study we found only 1 patient to be non compliant due to 
myalgia. This patient was started on Imatinib and had grade 3 pain. Imatinib 
had to be stopped for the same and his pain was relieved by NSAIDs. He had 
decreased phosphate levels from baseline but not in range of 
hypophosphatemia. 
 
 Pediatric CML and Imatinib: Pediatric CML accounts for nearly 3% 
of pediatric leukemias.Imatinib has now nearly replaced allogenic stem cell 
transplant as a first line option in pediatric patients. However the data 
regarding long term effects in the treated pediatric patients is awaited. One of 
the toxicities is that of decreased linear growth in prepubertal age in patients 
on Imatinib. We also in our study had one patient 5 years of age  in our study 
for whom the father complained of no increase in height nearly after a year of 
being started on Imatinib. This again throws light on the Serum electrolyte 
imbalances due to decreased bone resorption.
33,35
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CONCLUSION 
 
This study highlights the following factors: 
 Myalgia and musculoskeletal is the one of the common 
nonhematological side effect in patients of chronic myeloid leukemia who are 
initiated on imatinib. In our study it was the most common one. 
 
 Generalized myalgia and bone pains is the most common presentation 
in a patient who is started on Imatinib, this is usually a Grd1/2 pain and it 
usually presents in the first month of starting Imatinib and the response to 
NSAIDs alone or with calcium supplementation is good (91%). 
 
 There is a trend for decrease in Serum Calcium, and Phosphate levels 
as earlier reported in literature. Since there is increase in Fractional 
excretion of phosphate, considering this the most common etiology could be 
secondary hyperparathyroidism,although we did not look for serum 
Parathyroid levels in our study. This trend of decrease in electrolyte levels 
continues even after the myalgia and musculoskeletal pain is relieved , we 
found the trend even at 6 months.This is especially important for calcium 
where the difference in 6 monthly values was quite significantly low when 
compared to our normal controls. 
61 
 However we could not find a statistical significance of myalgia and 
musculoskeletal pain in patients who had relative hypophosphatemia and 
hypocalcemia, probably because of a small sample size but nonetheless this 
probably high lights the importance of measuring the serum electrolyte levels 
and bone mineral density especially in a pediatric and elderly age group who 
are on Imatinib  where altered bone metabolism can make an impact on 
genral health. 
 
 We found a near statsical significance(p=0.07) in patients having 
myalgia and those with low potassium values. There is not much evidence for 
this finding except for case reports,  further studies are required to confirm 
this finding. 
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Proforma: Prospective evaluation of myalgia& 
musculoskeletal pain in patients of CML –chronic phase 
treated with Imatinib AND possible corelation with electrolyte 
imbalances- 
 
BASELINE EVALUATION 
Pt:  Name                             Age                            Sex      
UHID                  CIndex 
Tel No. 
HISTORY OF MUSCULOSKELETAL DISORDER                    Y  /  N 
DRUG INTAKE             (PLEASE SPECIFY)                       ______________________ 
Imatinib starting Date______________ 
 
 Responses  disease  at 
o 3m 
o 6m 
 Side effects of Imatinib(other than myalgia) 
 Compliance issue due  to side effects 
 Compliance issue related to musculoskeletal event(y/N) 
o Myalgia/ Musculoskeletal pain (y/N) 
o Grd 
 
o Duration(months) 
o Effect  of  adding  analgesics (grd) &Effect  of  Calcium 
supplementation (grd) 
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At Follow Up 
 
 
CTC grade 2.0 
 
 
 
 
 
 
 
 
 Myalgia 
Grd  
 
Respone  
Of disease 
Cr Na+ Ca2+ K + PO4+ Urine 
spot 
Creatin
ine 
Urine 
spot 
PO4 
Serum 
Albumin 
At 
baseline 
          
At 3m           
At 6 m           
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ABBREVIATIONS 
  
 
  CML: Chronic myeloid leukemia 
  Ph chromosome : Philadelphia chromosome 
 CCyR: Complete Cytogenetic response 
 GIPAP: Glivec  International  Patient Assisted Programme 
 NSAIDs: Non Steroidal anti  Inflammatory Drug 
 Ca2+: serum calcium /ionized Calcium 
 K+: Serum Potassium 
 PO 4 : Serum Phosphate 
 Na +: Serum Sodium  
 
 
